|
1）Easwaran H， Tsai HC， Baylin SB. Cancer epigenetics: tumor heterogeneity， plasticity of stem-like states， and drug resistance. Mol Cell. 2014; 54: 716-27
|
|
|
|
2）Baylin SB， Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer. 2011; 11: 726-34
|
|
|
|
|
|
3）Shih AH， Abdel-Wahab O， Patel JP， et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12: 599-612
|
|
|
|
|
|
4）Aumann S， Abdel-Wahab O. Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochem Biophys Res Commun. 2014; 455: 24-34
|
|
|
|
|
|
5）Wu H， Zhang Y. Reversing DNA methylation: mechanisms， genomics， and biological functions. Cell. 2014; 156: 45-68
|
|
|
|
|
|
6）Yan XJ， Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-15
|
|
|
|
|
|
7）Challen GA， Sun D， Jeong M， et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011; 44: 23-31
|
|
|
|
|
|
8）Cimmino L， Abdel-Wahab O， Levine RL， et al. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011; 9: 193-204
|
|
|
|
|
|
9）Losman JA， Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH， (R)-2-hydroxyglutarate， and cancer. Genes Dev. 2013; 27: 836-52
|
|
|
|
|
|
10）Dawson MA， Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150: 12-27
|
|
|
|
|
|
11）Chi P, Allis CD, Wang GG. Covalent histone modifications－miswritten， misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10: 457-69
|
|
|
|
|
|
12）Roy DM， Walsh LA， Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014; 5: 265-96
|
|
|
|
|
|
13）Sauvageau M， Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 3010; 7: 299-313
|
|
|
|
|
|
14）Laugesen A， Helin K. Chromatin repressive complexes in stem cells， development， and cancer. Cell Stem Cell. 2014; 14: 735-51
|
|
|
|
|
|
15）Muto T， Sashida G， Oshima M， et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med. 2013; 210: 2627-39
|
|
|
|
|
|
16）De Raedt T， Beert E， Pasmant E， et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014; 514: 247-51
|
|
|
|
|
|
17）Lewis PW， Muller MM， Koletsky MS， et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340: 857-61
|
|
|
|
|
|
18）Gui Y， Guo G， Huang Y， et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011; 43: 875-8
|
|
|
|
|
|
19）Peifer M， Fernández-Cuesta L， Sos ML， et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44: 1104-10
|
|
|
|
|
|
20）Manceau G， Letouzé E， Guichard C， et al. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Int J Cancer. 2013; 132: 2217-21
|
|
|
|
|
|
21）Reisman DN， Sciarrotta J， Wang W， et al. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003; 63: 560-6
|
|
|
|
|